Flagship Ventures

Latest Headlines

Latest Headlines

Flagship banks $537M to back the next batch of biotechs

Biotech VC stalwart Flagship Ventures put together a $537 million new fund, its largest ever, with eyes on a new generation of life sciences upstarts.

Seres bags another $10M to gut it out in microbiomics

Biotech Seres Health has raised a quick $10 million B round to support its work in microbiome R&D, appending a partnership with the Mayo Clinic as it advances an infectious disease treatment.

Flagship Ventures launches a biotech on the human microbiome sea

After two years of building up its knowledge of the human microbiome, tiny Seres Health has emerged from stealth mode today with $10.5 million in venture cash from Flagship Ventures and a business plan to develop new therapies dubbed "Ecobiotics."

Langer biotech adds $16M in venture cash to back next-gen cancer drugs

The startup biotech Blend Therapeutics rang in 2012 with seed cash and will now close out the year with a fresh injection of $16 million in B-round bucks budgeted to take this startup--one of the latest from the prolific scientist Robert Langer--right to the threshold of clinical development.

Biotech upstart Moderna nails down $40M for bold RNA idea

The secretive startup has attracted $40 million from Flagship Ventures and other investors to put the bold plan into action, disclosing the financing and details about its research to the public for the first time this morning.

Dx startup Quanterix draws major bioMérieux investment

French in vitro diagnostics giant bioMérieux has taken a major stake in Massachusetts startup Quanterix. It led most of a $18.5 million Series C financing secured by the company, and both will partner to develop ultrasensitive and multilevel immunoassays.

Gates Foundation backs $13M venture add for flu drug developer

The Bill & Melinda Gates Foundation has stepped up with another equity investment in a biotech company, this time making a major contribution to a $13 million Series A add for a startup aiming at a universal preventive as well as therapeutic approach to influenza. Omega Funds also joined the venture top-up, bringing the first venture round for Cambridge, MA-based Visterra to $26 million.

Flagship Ventures CEO keeps Merck aboard to inform biotech bets

Gone are the days when venture capitalists could hatch a biotech and take it public without much regard for the needs of Big Pharma. Public investors seldom buy into new biotech companies, and drugmakers have increasingly become early partners with VC firms and their young ventures. In the process, pharma has gained significant clout in the biotech VC game.

Biotech vet Connelly whips up a recipe for 'delicious' packaging upstart

Robert Connelly has stepped aside from his job at the helm of Lexington, MA-based Pulmatrix, trading in his role leading the development of new respiratory drugs in favor of a new trans-Atlantic upstart which plans to create a wide range of "delicious" packages for food designed to replace today's trash with a tasty snack.

Seventh Sense scores $10M Series A for blood collection device

Seventh Sense Biosystems scored a $10 million round of Series A financing designed to help launch a pivotal clinical trial for its point of care blood collection device.